|

New Surgery Gives Better Odds of Surviving Mesothelioma

New Surgery Gives Better Odds of Surviving Mesothelioma

A surgery that removes the lining around the lung may give patients better odds of surviving mesothelioma. The surgery is known as pleurectomy decortication (PD). And it may give better odds than extrapleural pneumonectomy (EP). These two surgical procedures are the most used procedures for resectable malignant mesothelioma.

A new article in the Journal of Clinical Medicine describes an analysis of mesothelioma survival after surgery.

Surgical Treatment for Mesothelioma

Malignant mesothelioma is a rare and aggressive cancer that rarely responds to a single cancer therapy. Malignant mesothelioma is caused by exposure to asbestos. Usually, that happens in the workplace.

Pleurectomy decortication is a two-part surgical procedure to treat mesothelioma. The first stage removes the membrane surrounding the lung. The second stage removes diseased tissue that has grown on or around the lung.

Extrapleural pneumonectomy involves removing the lung affected by mesothelioma. Part of the diaphragm and the linings of the lung and heart are also removed. The goal is to remove all visible cancer.

These surgical procedures are often combined with other treatments like chemotherapy and radiation.

Better Chance of Survival?

Researchers from Italy looked at the odds of survival after these two procedures. They also compared the rates of postoperative complications. They compared the results of 13 studies published through May 2022.

The team found that patients had improved long-term survival after receiving PD surgery. Patients who received PD had a much lower risk of death 30 days after surgery.

These patients also had fewer complications after surgery than patients treated with EP. These complications included bacterial infection, irregular heart beat, and bleeding.

Researchers conclude that pleurectomy decortication has better long-term survival over extrapleural pneumonectomy.

Source

Danuzzo F, Maiorca S, Bonitta G, Nosotti M. Systematic Review and Meta-Analysis of Pleurectomy/Decortication versus Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma. J Clin Med. 2022 Sep 22;11(19):5544. doi: 10.3390/jcm11195544. PMID: 36233416; PMCID: PMC9571799. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571799/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…